{"drugs":["Diflunisal","Dolobid"],"mono":[{"id":"179115-s-0","title":"Generic Names","mono":"Diflunisal"},{"id":"179115-s-1","title":"Dosing and Indications","sub":[{"id":"179115-s-1-4","title":"Adult Dosing","mono":"<ul><li>use lowest effective dose for shortest possible duration<\/li><li>after observing initial response, adjust dose and frequency to meet individual patient's needs<\/li><li><b>Osteoarthritis:<\/b> 500 to 1000 mg ORALLY daily in 2 divided doses; MAX 1500 mg\/day<\/li><li><b>Pain (Mild to Moderate):<\/b> initial, 1000 mg ORALLY for 1 dose<\/li><li><b>Pain (Mild to Moderate):<\/b> maintenance, 250 to 500 mg ORALLY every 8 to 12 h<\/li><li><b>Rheumatoid arthritis:<\/b> 500 to 1000 mg ORALLY daily in 2 divided doses; MAX 1500 mg\/day<\/li><\/ul>"},{"id":"179115-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy in children less than 12 y old have not been established<\/li><li>use lowest effective dose for shortest possible duration<\/li><li>after observing initial response, adjust dose and frequency to meet individual patient's needs<\/li><\/ul>"},{"id":"179115-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> begin with lowest recommended dosage, monitor patient closely; a 50% reduction in dose for those with CrCL less than 50 mL\/min has been recommended<\/li><li><b>elderly:<\/b> begin with the lowest recommended dosage, monitor patient closely<\/li><\/ul>"},{"id":"179115-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Osteoarthritis<\/li><li>Pain (Mild to Moderate)<\/li><li>Rheumatoid arthritis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Backache<\/li><li>Dysmenorrhea<\/li><li>Soft tissue injury<\/li><\/ul>"}]},{"id":"179115-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may be increased in patients with cardiovascular disease or risk factors for cardiovascular disease. Diflunisal is contraindicated for the treatment of perioperative pain in the setting of CABG surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events especially in the elderly, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.<br\/>"},{"id":"179115-s-3","title":"Contraindications\/Warnings","sub":[{"id":"179115-s-3-9","title":"Contraindications","mono":"<ul><li>asthma, urticaria, or allergic-type reaction following administration of aspirin or other NSAIDs; severe anaphylactic-like reactions have been reported, including rare fatalities<\/li><li>CABG surgery, treatment of perioperative pain<\/li><li>hypersensitivity to any component<\/li><\/ul>"},{"id":"179115-s-3-10","title":"Precautions","mono":"<ul><li>cardiovascular thrombotic events; myocardial infarction, stroke, and fatalities have been reported; risk may increase with duration of use<\/li><li>cardiovascular disease, known or risk factors for; increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke<\/li><li>elderly; increased risk of serious gastrointestinal adverse events (bleeding, ulceration, perforation of stomach or intestines) that can occur at any time and without warning; increased risk of renal toxicity or injury; monitoring recommended<\/li><li>gastrointestinal adverse events; ulceration, bleeding, or perforation of stomach or intestines, potentially fatal may occur without warning; increased risk with concurrent use of aspirin, corticosteroids, or anticoagulants, smoking, alcohol use, or poor general health status; monitoring recommended<\/li><li>anaphylaxis and anaphylactoid reactions have occurred<\/li><li>anemia may occur; monitoring recommended<\/li><li>aspirin triad (bronchospasm in asthmatic patients with rhinitis, with or without nasal polyps following aspirin or NSAID administration); risk of severe, potentially fatal bronchospasm; use not recommended<\/li><li>asthma, preexisting; risk of severe and potentially fatal bronchospasm<\/li><li>chicken pox, influenza, or flu-like symptoms; diflunisal is a derivative of aspirin; potential to increase risk of Reye's syndrome<\/li><li>coagulation disorders or concomitant use of anticoagulation agents; may be adversely affected by inhibition of platelet aggregation; monitoring recommended<\/li><li>extended duration of therapy; increased risk of potentially fatal gastrointestinal bleeding, ulceration, or perforation that may occur without warning; increased risk of renal papillary necrosis and other renal injury<\/li><li>fluid retention and edema have been reported<\/li><li>gastrointestinal bleeding, history; increased risk of ulceration or perforation of stomach or intestines, potentially fatal; monitoring recommended<\/li><li>heart failure; edema and fluid retention have been reported; increased risk of renal toxicity or injury<\/li><li>hepatic dysfunction; increased risk of renal toxicity and liver injury<\/li><li>hepatic reactions, including liver enzyme abnormalities, jaundice, fatal fulminant hepatitis, liver necrosis, and hepatic failure have been reported; monitoring recommended; discontinue use with signs or symptoms, or systemic evidence of hepatic reactions<\/li><li>hypersensitivity syndrome, potentially fatal, multi-organ reactions have been reported; discontinue use if suspected<\/li><li>hypertension; new onset or exacerbation may occur<\/li><li>peptic ulcer disease, history; increased risk of bleeding, or perforation of stomach or intestines, potentially fatal; monitoring recommended<\/li><li>platelet aggregation inhibition occurs; may result in prolonged bleeding time<\/li><li>renal disease, advanced; use is not recommended<\/li><li>renal impairment; increased risk of renal toxicity or injury; monitoring recommended<\/li><li>renal papillary necrosis and other renal injury may occur; increased risk in patients who are volume-depleted, or with concurrent use of ACE inhibitors and diuretics; consider discontinuing therapy<\/li><li>skin reactions; potentially fatal adverse events including exfoliative dermatitis, Stevens Johnson syndrome, and toxic epidermal necrolysis may occur; discontinue use with first appearance of rash or other sign<\/li><li>visual changes have been reported with NSAID use<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"179115-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"179115-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"179115-s-4","title":"Drug Interactions","sub":[{"id":"179115-s-4-13","title":"Contraindicated","mono":"<ul>Ketorolac (theoretical)<\/ul>"},{"id":"179115-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clopidogrel (probable)<\/li><li>Clovoxamine (probable)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Desirudin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Femoxetine (probable)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Methotrexate (theoretical)<\/li><li>Milnacipran (probable)<\/li><li>Nadroparin (probable)<\/li><li>Nefazodone (probable)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Phenprocoumon (probable)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Sibutramine (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Zimeldine (probable)<\/li><\/ul>"},{"id":"179115-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Acenocoumarol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Anisindione (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cilazapril (established)<\/li><li>Clopamide (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dicumarol (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perindopril (established)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>Talinolol (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Warfarin (probable)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},{"id":"179115-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Body fluid retention<\/li><li><b>Dermatologic:<\/b>Rash (3% to 9%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (1.9% to 9%), Constipation (1% to 3%), Diarrhea (3% to 9%), Flatulence (1% to 3%), Indigestion (3% to 9%), Nausea (3% to 9.5%), Vomiting (1% to 3%)<\/li><li><b>Neurologic:<\/b>Dizziness (1% to 3%), Headache (3% to 9%), Insomnia (1% to 3%), Somnolence (1% to 3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction, Thrombotic tendency observations<\/li><li><b>Dermatologic:<\/b>Erythroderma, Stevens-Johnson syndrome (less than 1%), Toxic epidermal necrolysis (less than 1%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (less than 1%), Gastrointestinal perforation (less than 1%), Gastrointestinal ulcer (less than 1%)<\/li><li><b>Hematologic:<\/b>Agranulocytosis (less than 1%), Thrombocytopenia (less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatic necrosis, Hepatitis (less than 1%), Increased liver function test (up to 15%), Jaundice (less than 1%)<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction (less than 1%), Hypersensitivity reaction<\/li><li><b>Musculoskeletal:<\/b>Fasciitis<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><li><b>Renal:<\/b>Interstitial nephritis (less than 1%), Renal failure (less than 1%), Renal impairment (less than 1%)<\/li><li><b>Respiratory:<\/b>Bronchospasm<\/li><li><b>Other:<\/b>Angioedema (less than 1%), Reye's syndrome<\/li><\/ul>"},{"id":"179115-s-6","title":"Drug Name Info","sub":{"0":{"id":"179115-s-6-17","title":"US Trade Names","mono":"Dolobid<br\/>"},"2":{"id":"179115-s-6-19","title":"Class","mono":"<ul><li>Analgesic<\/li><li>NSAID<\/li><li>Salicylate, Non-Aspirin<\/li><\/ul>"},"3":{"id":"179115-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"179115-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"179115-s-7","title":"Mechanism Of Action","mono":"Diflunisal is a nonsteroidal anti-inflammatory drug with antipyretic property. It is a peripherally-acting non-narcotic analgesic that inhibits prostaglandin synthetase resulting in decreased prostaglandin, which is a known mediator of pain and inflammation.<br\/>"},{"id":"179115-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"179115-s-8-23","title":"Absorption","mono":"Oral, time to peak concentration: 2 h to 3 h <br\/>"},"1":{"id":"179115-s-8-24","title":"Distribution","mono":"Protein binding: more than 99% <br\/>"},"3":{"id":"179115-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: little or none<\/li><li>Renal: 90% as glucuronide conjugates<\/li><\/ul>"},"4":{"id":"179115-s-8-27","title":"Elimination Half Life","mono":"8 h to 12 h <br\/>"}}},{"id":"179115-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with water, milk, or meals<\/li><li>do not crush or chew; swallow whole<\/li><\/ul>"},{"id":"179115-s-10","title":"Monitoring","mono":"<ul><li>rheumatoid arthritis\/osteoarthritis: improved range of motion, decreased early morning stiffness and painful\/swollen joints, C-reactive protein levels, erythrocyte sedimentation rate<\/li><li>pain: relief of pain<\/li><li>CBC, chemistry profile, blood pressure, fecal occult blood test, liver function; after initiation of NSAID therapy and every 6-12 months thereafter, more frequently in patients at risk for hepatic, renal, cardiac, or gastrointestinal toxicity (eg, age greater than 60 years, high-dose NSAID therapy, concurrent corticosteroids or anticoagulants, history of cardiac, renal, or hepatic disease)<\/li><li>hemoglobin, hematocrit; in patients with signs\/symptoms of anemia<\/li><li>signs and symptoms of skin reaction<\/li><\/ul>"},{"id":"179115-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 250 MG, 500 MG<br\/><\/li><li><b>Dolobid<\/b><br\/>Oral Tablet: 500 MG<br\/><\/li><\/ul>"},{"id":"179115-s-12","title":"Toxicology","sub":[{"id":"179115-s-12-31","title":"Clinical Effects","mono":"<b>DIFLUNISAL<\/b><br\/>OVERDOSE: Drowsiness, disorientation, vomiting, diarrhea, tachycardia, sweating, tinnitus, and stupor\/coma are possible. Sudden deterioration has occurred 8-10 hours after a massive overdoses. Diminished urine output, hepatotoxicity and cardiorespiratory arrest have occurred. <br\/>"},{"id":"179115-s-12-32","title":"Treatment","mono":"<b>DIFLUNISAL <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Therapy as indicated; no specific therapy for diflunisal overdose.<\/li><li>Acidosis: Sodium Bicarb 1-2mEq\/kg IV, monitor arterial pH and blood gases to guide treatment<\/li><li>Monitoring of patient: Monitor acid-base &amp; fluid status, temperature, and cardiorespiratory function<\/li><li>Tachyarrhythmia: IV propranolol if hemodynamically unstable. Adult - 1mg\/dose over 1 min; maximum 5mg.  Child - 0.01-0.1mg\/kg\/dose over 10 min; maximum 1mg\/dose.<\/li><li>Hypotensive episode: 0.9% NaCl 10-20ml\/kg IV, dopamine or norepinephrine.<\/li><\/ul>"},{"id":"179115-s-12-33","title":"Range of Toxicity","mono":"<b>DIFLUNISAL<\/b><br\/>Lowest lethal dose 15 grams; 7.5 grams have produced serious effects in some individuals. <br\/>"}]},{"id":"179115-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patients that due to risk of Reye's syndrome, drug should not be used in children without healthcare provider approval. Drug should never be used in children and teenagers with chickenpox or flu symptoms.<\/li><li>This drug may cause body fluid retention, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea, dizziness, headache, insomnia, tinnitus, or bronchospasm.<\/li><li>Advise patient to immediately report signs\/symptoms of cardiovascular thrombotic events, myocardial infarction, or stroke.<\/li><li>Patient should also report signs\/symptoms of gastrointestinal hemorrhage, ulceration, or perforation. Elderly and debilitated patients are at higher risk while taking this drug.<\/li><li>Patient should take tablet with food or milk to minimize gastric irritation.<\/li><li>Patient should not drink alcohol while taking this drug.<\/li><\/ul>"}]}